Skip to main content

InnovaTV207 SGNTV 001 Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors. SGNTV001

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Seagen, Inc

Start Date

March 12, 2024

End Date

April 15, 2029
 

Administered By

Duke Cancer Institute

Awarded By

Seagen, Inc

Start Date

March 12, 2024

End Date

April 15, 2029